JP2021528435A - ２つ以上の異なる抗体の制御された混合物を産生するための方法 - Google Patents

２つ以上の異なる抗体の制御された混合物を産生するための方法 Download PDF

Info

Publication number
JP2021528435A
JP2021528435A JP2020571498A JP2020571498A JP2021528435A JP 2021528435 A JP2021528435 A JP 2021528435A JP 2020571498 A JP2020571498 A JP 2020571498A JP 2020571498 A JP2020571498 A JP 2020571498A JP 2021528435 A JP2021528435 A JP 2021528435A
Authority
JP
Japan
Prior art keywords
antibodies
antibody
mixture
igg1
different antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020571498A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021528435A5 (https=
Inventor
リチャード ヒバート
ヨング ロブ デ
アラン フランク ラブリン
アルナウト ゲリツェン
ジャニーヌ スフールマン
ポール パレン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genmab AS
Original Assignee
Genmab AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genmab AS filed Critical Genmab AS
Publication of JP2021528435A publication Critical patent/JP2021528435A/ja
Publication of JP2021528435A5 publication Critical patent/JP2021528435A5/ja
Priority to JP2024086125A priority Critical patent/JP2024109884A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2020571498A 2018-06-22 2019-06-24 ２つ以上の異なる抗体の制御された混合物を産生するための方法 Pending JP2021528435A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024086125A JP2024109884A (ja) 2018-06-22 2024-05-28 ２つ以上の異なる抗体の制御された混合物を産生するための方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18179365 2018-06-22
EP18179365.4 2018-06-22
PCT/EP2019/066594 WO2019243626A1 (en) 2018-06-22 2019-06-24 Method for producing a controlled mixture of two or more different antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024086125A Division JP2024109884A (ja) 2018-06-22 2024-05-28 ２つ以上の異なる抗体の制御された混合物を産生するための方法

Publications (2)

Publication Number Publication Date
JP2021528435A true JP2021528435A (ja) 2021-10-21
JP2021528435A5 JP2021528435A5 (https=) 2022-07-01

Family

ID=62841830

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020571498A Pending JP2021528435A (ja) 2018-06-22 2019-06-24 ２つ以上の異なる抗体の制御された混合物を産生するための方法
JP2024086125A Pending JP2024109884A (ja) 2018-06-22 2024-05-28 ２つ以上の異なる抗体の制御された混合物を産生するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024086125A Pending JP2024109884A (ja) 2018-06-22 2024-05-28 ２つ以上の異なる抗体の制御された混合物を産生するための方法

Country Status (9)

Country Link
US (1) US12247065B2 (https=)
EP (1) EP3810649A1 (https=)
JP (2) JP2021528435A (https=)
CN (1) CN112513074A (https=)
CA (1) CA3104390A1 (https=)
IL (1) IL279528A (https=)
MA (1) MA52945A (https=)
SG (1) SG11202012713RA (https=)
WO (1) WO2019243626A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI874341B (zh) 2018-12-18 2025-03-01 美商健生生物科技公司 產生異二聚體抗體之方法
JP7778705B2 (ja) 2020-02-21 2025-12-02 ジェンマブ ビー．ブイ． 糖蛋白質の定量のための方法
EP4372001A4 (en) * 2021-07-14 2025-02-12 Jiangsu Hengrui Pharmaceuticals Co., Ltd. ANTIGEN-BINDING MOLECULE SPECIFICALLY BINDING TO HGFR AND EGFR, AND PHARMACEUTICAL USE THEREOF
EP4624493A1 (en) * 2022-11-24 2025-10-01 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition comprising bispecific antibody specifically binding to hgfr and egfr
TW202509077A (zh) * 2023-06-30 2025-03-01 丹麥商珍美寶股份有限公司 與纖維母細胞活化蛋白α及死亡受體４結合之抗體

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07206708A (ja) * 1993-12-27 1995-08-08 Rotkreuzstiftung Zentral Lab Blutspendedienst Srk 抗ｄ−免疫グロブリンｇの濃縮物の製造方法、それを含む製薬的調剤
JP2008506960A (ja) * 2004-07-20 2008-03-06 シムフォゲン・アクティーゼルスカブ 組換えポリクローナルタンパク質またはポリクローナル細胞株を構造上特徴付ける方法
JP2008509658A (ja) * 2004-07-20 2008-04-03 シムフォゲン・アクティーゼルスカブ 抗−ＲｈＤ組換えポリクローナル抗体及び製造方法
JP2011518790A (ja) * 2008-04-23 2011-06-30 シムフォゲン・アクティーゼルスカブ ポリクローナルタンパク質を製造する方法
JP2015510764A (ja) * 2012-03-13 2015-04-13 ノビミューン エスアー 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体
JP2015529236A (ja) * 2012-09-25 2015-10-05 グレンマーク ファーマシューティカルズ， エセ．アー． ヘテロ二量体免疫グロブリンの精製

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
JP4593783B2 (ja) 1998-07-21 2010-12-08 ゲンマブ・アクティーゼルスカブ 抗ｃ型肝炎ウイルス抗体およびその使用
CA2450285C (en) 2001-06-13 2016-08-02 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (egfr)
DK2314629T4 (da) 2002-07-18 2023-02-06 Merus Nv Rekombinant produktion af blandinger af antistoffer
BRPI0315295C1 (pt) 2002-10-17 2021-05-25 Genmab As anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão
SI1583830T1 (sl) 2003-01-07 2006-12-31 Symphogen As Postopek za pripravo rekombinantnih poliklonskih proteinov
EP2009101B1 (en) 2006-03-31 2017-10-25 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
MX2009012526A (es) * 2007-05-25 2009-12-09 Symphogen As Metodo para fabricar una proteina policlonal recombinante.
WO2010089387A1 (en) 2009-02-09 2010-08-12 Morphosys Ag Production of oligoclonal mixtures of immunoglobulins in single cells
MY192182A (en) 2009-06-26 2022-08-04 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
SG10201501803YA (en) 2010-03-12 2015-05-28 Immunogen Inc Cd37-binding molecules and immunoconjugates thereof
HRP20241208T1 (hr) 2010-04-20 2024-11-22 Genmab A/S Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju
CA2800769C (en) 2010-05-27 2021-11-02 Genmab A/S Monoclonal antibodies against her2 epitope
WO2012068317A2 (en) 2010-11-16 2012-05-24 Excelimmune, Inc. Methods for producing recombinant proteins
CN103796678B (zh) 2011-04-20 2018-02-27 健玛保 针对her2的双特异性抗体
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
PT2768857T (pt) 2011-10-19 2020-01-27 Novimmune Sa Métodos para purificar anticorpos
KR20200024345A (ko) 2013-01-10 2020-03-06 젠맵 비. 브이 인간 IgG1 Fc 영역 변이체 및 그의 용도
HK1222871A1 (zh) 2013-05-13 2017-07-14 Medimmune, Llc 具有最小单体分离的重组多克隆抗体多聚体的分离
SMT202000265T1 (it) 2014-07-11 2020-07-08 Genmab As Anticorpi che legano axl
EP3233907B1 (en) * 2014-12-19 2021-03-03 Genmab A/S Rodent bispecific heterodimeric proteins
US12595316B2 (en) 2015-07-09 2026-04-07 Genmab A/S Bispecific and multispecific antibodies and method for isolation of such
US11020686B2 (en) * 2016-08-16 2021-06-01 Regeneron Pharmaceuticals, Inc. Methods for quantitating individual antibodies from a mixture

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07206708A (ja) * 1993-12-27 1995-08-08 Rotkreuzstiftung Zentral Lab Blutspendedienst Srk 抗ｄ−免疫グロブリンｇの濃縮物の製造方法、それを含む製薬的調剤
JP2008506960A (ja) * 2004-07-20 2008-03-06 シムフォゲン・アクティーゼルスカブ 組換えポリクローナルタンパク質またはポリクローナル細胞株を構造上特徴付ける方法
JP2008509658A (ja) * 2004-07-20 2008-04-03 シムフォゲン・アクティーゼルスカブ 抗−ＲｈＤ組換えポリクローナル抗体及び製造方法
JP2011518790A (ja) * 2008-04-23 2011-06-30 シムフォゲン・アクティーゼルスカブ ポリクローナルタンパク質を製造する方法
JP2015510764A (ja) * 2012-03-13 2015-04-13 ノビミューン エスアー 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体
JP2015529236A (ja) * 2012-09-25 2015-10-05 グレンマーク ファーマシューティカルズ， エセ．アー． ヘテロ二量体免疫グロブリンの精製

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SOREN K. RASMUSSEN ET AL.: "Recombinant antibody mixtures: Production strategies and cost considerations", ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, vol. 526, JPN7024003974, 2012, pages 139 - 145, ISSN: 0005419627 *

Also Published As

Publication number Publication date
IL279528A (en) 2021-01-31
SG11202012713RA (en) 2021-01-28
CA3104390A1 (en) 2019-12-26
JP2024109884A (ja) 2024-08-14
US12247065B2 (en) 2025-03-11
CN112513074A (zh) 2021-03-16
EP3810649A1 (en) 2021-04-28
WO2019243626A1 (en) 2019-12-26
MA52945A (fr) 2021-04-28
US20210269509A1 (en) 2021-09-02

Similar Documents

Publication Publication Date Title
US20250257120A1 (en) Compositions comprising a tn3 scaffold and methods of using the same
US12247065B2 (en) Method for producing a controlled mixture of two or more different antibodies
EP3227328B1 (en) Domain-exchanged antibody
CA3099509C (en) Multispecific antibodies
JP2021130690A (ja) 二重特異性タンパク質およびその製造方法
US11591409B2 (en) Anti-PD-L1/anti-PD-1 natural antibody structure-like heterodimeric bispecific antibody and preparation thereof
US20150038682A1 (en) Antibodies or fusion proteins multimerized via homomultimerizing peptide
CN113301919A (zh) 激活免疫细胞的双特异性抗体
KR20190021255A (ko) 유전자 조작 Fc 작제물에 관한 조성물 및 방법
WO2010071208A1 (ja) 抗体の精製方法
CN113395978A (zh) 与靶向CTLA-4的工程化Fc-抗原结合结构域构建体有关的组合物和方法
CN113164591A (zh) 与工程化Fc-抗原结合结构域构建体有关的组合物和方法
KR20190099333A (ko) 유전자 조작 Fc 작제물에 관한 조성물 및 방법
CN113194990A (zh) 与靶向CD38的工程化Fc-抗原结合结构域构建体有关的组合物和方法
JP7734075B2 (ja) 疑似ｆａｂベースの多重特異性結合タンパク質
CN113164590A (zh) 与靶向CCR4的工程化Fc-抗原结合结构域构建体有关的组合物和方法
CN112996910A (zh) 与靶向PD-L1的工程化Fc-抗原结合结构域构建体有关的组合物和方法
KR20260047593A (ko) 최적화된 Fc 분자
HK40049533A (en) Method for producing a controlled mixture of two or more different antibodies
CN113164592A (zh) 与工程化Fc-抗原结合结构域构建体有关的组合物和方法
HK40103459A (en) Multispecific mutated antibody fab fragments
TW202409093A (zh) 融合蛋白
HK40058120B (en) Multispecific mutated antibody fab fragments
HK40058120A (en) Multispecific mutated antibody fab fragments
HK40090436A (zh) Cd40l-特异性tn3-衍生的支架及其使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220623

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220623

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230517

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230529

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230828

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231129

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20231227

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240528

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240605

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20240920